TRT Injection Frequency: Once vs Twice a Week, Explained With Blood Levels
TRT Injection Frequency: Once vs Twice a Week, Explained With Blood Levels
TRT injection frequency is how often a fixed weekly dose of testosterone is split up: 200 mg every two weeks, 100 mg once a week, 50 mg twice a week, or smaller doses every other day. The total is the same; what changes is the shape of the blood level between injections. That shape decides how high the peak goes, how low the trough falls, how much estradiol and hematocrit rise, and how stable a man feels. This guide walks through the pharmacokinetic data behind each option.
Educational content. MuscleScience does not prescribe, sell or supply testosterone and does not recommend individual doses or schedules. Injection frequency is a prescribing decision that belongs with a licensed clinician.
TRT Injection Frequency: 3 Things the Pharmacokinetic Studies Show
The TRT injection frequency argument about once versus twice a week is usually settled with anecdotes. It does not need to be. The peak-and-trough behaviour of injectable testosterone esters has been measured directly, and the numbers are consistent across four decades of studies.
After a 200 mg intramuscular cypionate injection, total testosterone rises about threefold and estradiol about threefold, peaking on days 2 to 5; many men are above the normal range from day 2 to day 7, and levels are back to baseline by days 13 to 14 (Nankin 1987).
With weekly subcutaneous cypionate, seven samples spread across the dosing week averaged 627 ng/dL (SD 206), with both total and free testosterone staying within the normal range throughout (McFarland 2017).
The Endocrine Society lists enanthate or cypionate at 75 to 100 mg weekly or 150 to 200 mg every two weeks, and injectable undecanoate 750 mg at weeks 0 and 4, then every 10 weeks. Levels are measured midway between injections and aimed at the mid-normal range.
The unit that matters is milligrams per week, not per injection. 100 mg weekly, 50 mg twice weekly and 200 mg fortnightly all deliver the same average exposure; the average level at steady state is nearly identical. TRT injection frequency changes the swing around that average, and the swing is what drives most side effects and most symptom complaints.
Why the ester half-life sets the swing, with the measured peak and trough data for cypionate and enanthate.
Every option side by side: fortnightly, weekly, twice weekly, every other day, long-acting undecanoate and daily gel.
What frequency changes on bloodwork: hematocrit, estradiol, symptom stability and the timing of the lab draw.
Subcutaneous versus intramuscular, and the mistakes that make a frequency change look like it failed.
Why Injection Frequency Matters: The Ester Sets the Shape
Testosterone cypionate and enanthate are testosterone with a fatty-acid ester attached. The ester makes the molecule oil-soluble, so it sits in the injection depot and is released slowly, and enzymes then clip the ester off to release active testosterone. The release is not steady. It is fast in the first days and then tails off, which is why the blood level climbs to a peak and then decays. The elimination half-life of testosterone enanthate is roughly 4 to 5 days; cypionate behaves similarly, with a slightly longer tail. That half-life is the whole story of injection frequency: the longer the gap between injections relative to the half-life, the deeper the trough and, because the dose per injection has to be larger to compensate, the higher the peak.
The curves are modeled from a 4.5-day half-life for the same 100 mg per week; they are illustrative rather than measured, but they match the measured pattern. Dobs 1999 compared 200 mg enanthate every two weeks with a transdermal patch in hypogonadal men and found that the injections produced supraphysiological testosterone, bioavailable testosterone and estradiol for several days after each dose, while the daily patch kept morning levels in the normal range. Nankin's cypionate study found the same shape: peak on days 2 to 5, above-normal exposure through day 7, and a return to the untreated baseline by day 13 to 14. The last three or four days of a two-week interval are, hormonally, days without treatment.
A different view: how far a single 200 mg cypionate injection pushes each hormone above its pre-injection level in hypogonadal men (Nankin 1987, 11 men). Bars are fold-increase at peak.
The free and non-SHBG-bound fractions rise more than total testosterone because SHBG binding saturates at the peak, so a larger share of the extra hormone is unbound. That is why the peak days after a large injection feel different from the average level suggests, and why estradiol tracks the peak so closely. The SHBG guide and total vs free testosterone explain the binding side.
TRT Injection Frequency Compared: Every Two Weeks to Every Other Day
The table compares each TRT injection frequency at the same weekly total for the short esters, so only the split changes. Status reflects how the option scores on level stability and side-effect exposure, not on convenience, which is the trade-off the last column describes.
| Schedule | Peak and trough | Trade-off | Status |
|---|---|---|---|
| 200 mg every 2 weeks cypionate or enanthate, IM | Supraphysiological days 2 to 7; near baseline by day 13 to 14. The widest swing of any schedule. | Fewest injections; historically the standard schedule and still in the guideline. Most estradiol, most hematocrit rise, most mood and libido cycling. | ● Widest swing |
| 100 mg once a week IM or subcutaneous | Peak about 1.5 to 2x trough; trough stays in range at a normal dose. Weekly subcutaneous cypionate averaged 627 ng/dL across the week (McFarland 2017). | The current default in most clinics. One injection a week; modest swing that most men do not notice. | ● Standard |
| 50 mg twice a week IM or subcutaneous | Peak-to-trough ratio narrows to roughly 1.3x; steady-state levels close to flat. | Two injections a week. Lower peak estradiol and a smaller hematocrit rise than weekly for the same dose; the usual first step when either is a problem. | ● Most stable |
| 25 to 30 mg every other day, or daily microdosing subcutaneous | Essentially flat; the peak-to-trough difference is within lab variation. | Three to seven injections a week. Physiologically the closest to a gel. Chosen for men who are very sensitive to fluctuation; adherence is the limiting factor. | ● Flattest |
| Testosterone undecanoate 750 mg (US) or 1,000 mg (EU) IM, weeks 0 and 4, then every 10 to 14 weeks | Long-acting ester. After the loading doses, average 495 ng/dL over the 70-day interval with a mean maximum of 891 ng/dL; 94 percent of men stayed within the young-adult range on average (Morgentaler 2008). | Four to five clinic visits a year. Cannot be self-adjusted; a rare pulmonary oil microembolism reaction requires it to be given in a clinic with observation. | ● Stable, clinic-only |
| Daily transdermal gel for comparison | Physiological daily rhythm; no injection peak. Absorption varies between men and between days. | No needles; transfer risk to partners and children; 10 to 15 percent of men do not absorb enough. Lowest hematocrit effect of any form (Pastuszak 2015). | ● No peak |
Note what the TRT injection frequency table does not say: that more frequent is always better. The measured difference between weekly and twice weekly is real but modest, and a man who feels stable on 100 mg once a week with a normal hematocrit and no symptoms gains nothing from doubling his injections. TRT injection frequency is a tool for a specific problem, not a scoreboard.
4 Things TRT Injection Frequency Actually Changes
TRT injection frequency shows up in four places, and each one is a reason a clinician might split the dose rather than lower it.
Hematocrit: the peak drives red-cell production
Of all testosterone forms, injections raise hemoglobin and hematocrit the most (Pastuszak 2015), and the rise is dose-dependent (Coviello 2008). The stimulus is exposure above the normal range, which is exactly what the days after a large injection provide. Erythrocytosis is the most common lab reason a schedule gets changed: the Endocrine Society advises action at a hematocrit above 54 percent, and the usual sequence is smaller, more frequent doses first, a lower total dose or a switch to transdermal second. Detail in high hematocrit on TRT.
Estradiol: it follows the peak, not the average
Aromatization is proportional to the testosterone available, so estradiol rises threefold with the peak after a 200 mg injection (Nankin 1987) and stays supraphysiological for several days on a two-week schedule (Dobs 1999). Splitting the dose lowers the estradiol peak without touching the average, which is why frequency, not an aromatase inhibitor, is the first response to breast tenderness or fluid retention that appears in the days after an injection. See estradiol on TRT and water retention on TRT.
Symptoms: the trough is where the complaints live
Men on fortnightly injections classically describe a good first week and a flat, irritable, low-libido second week. On the measured curve that is days 10 to 14, when levels have fallen back toward the untreated baseline. Weekly dosing removes most of that cycle; twice-weekly removes nearly all of it. If symptoms track the calendar, frequency is the fix. If they are constant regardless of injection day, frequency will not help and the diagnosis or the dose needs revisiting.
Injection burden: the cost of stability
Each step toward flatter levels doubles the number of injections. Subcutaneous injections with a small insulin-type needle make twice weekly or every-other-day dosing tolerable for most men, but adherence, not pharmacology, is what usually decides whether a high TRT injection frequency survives. A schedule that gets skipped is worse than a slightly less stable one that gets done.
Subcutaneous vs Intramuscular: Does It Change the Frequency Decision?
Most of the TRT injection frequency debate assumes deep intramuscular injections, which is why fortnightly dosing persisted for so long: nobody wanted to do a glute injection twice a week. Subcutaneous injection into abdominal or thigh fat changes the calculation. In a cohort of 63 patients on weekly subcutaneous cypionate or enanthate, doses of 50 to 150 mg (median 75 to 80 mg) put every patient in the normal male range, across body mass indexes from 19 to 50, with only minor and transient injection-site reactions (Spratt 2017). McFarland's pharmacokinetic study in 11 patients on weekly subcutaneous cypionate showed total testosterone averaging 627 ng/dL across the whole week with no excursions outside the normal range.
The absorption profile from fat appears slightly slower and smoother than from muscle, which if anything reduces the peak further, and the practical effect is larger: a 0.5 mL subcutaneous injection with a short 27 to 30 gauge needle takes seconds and can be done without assistance, so twice-weekly and every-other-day schedules become realistic. Both routes are acceptable to the guidelines; the AUA guideline lists subcutaneous administration among the injectable options. The choice of route, like the choice of TRT injection frequency, is mostly about what a man will actually keep doing.
Switching from intramuscular to subcutaneous is not a reason to change the weekly milligrams. The bioavailability is comparable, and the guideline target does not move: mid-normal at the timed sample. Re-test 6 to 8 weeks after any change in route or frequency, at the new midpoint of the cycle, before concluding anything.
Where to Draw the Lab on Each Injection Schedule
The Endocrine Society instruction for cypionate and enanthate is to measure testosterone midway between injections and aim for the mid-normal range at that point. What "midway" means depends on the TRT injection frequency, and a lab drawn at the wrong point is the single most common reason a frequency change is judged wrongly.
| Schedule | When to draw | What a mid-normal result means | Status |
|---|---|---|---|
| Every 2 weeks | Day 7, midway. Many clinics also draw a day 13 to 14 trough to see how low it goes. | Midpoint in range with a trough near baseline is the classic case for moving to weekly. | ● Guideline |
| Weekly | Day 3 or 4, morning, fasting, before that day's training. | Peak and trough sit about 25 to 35 percent either side of the average; a mid-normal midpoint usually means an in-range trough. | ● Guideline |
| Twice weekly | Just before an injection (true trough), morning of injection day. | Levels are nearly flat, so the trough is close to the average; a mid-normal trough is the target. | ● Practice |
| Every other day or daily | Any morning before the injection; timing barely matters. | The reading is the average. Interpret exactly like a gel level. | ● Practice |
| Undecanoate every 10 weeks | End of the dosing interval, just before the next injection. | A trough below range means the interval is too long; the guideline adjusts the interval, not the dose. | ● Guideline |
Whatever the schedule, the CBC goes on the same requisition. Hematocrit is checked at baseline, at 3 to 6 months and then annually, and it does not depend on injection timing. The full panel, with reference ranges and the other action thresholds, is in the TRT bloodwork guide; the E2 to testosterone ratio calculator helps read an estradiol result against the testosterone drawn with it.
Choosing a TRT Injection Frequency: A Practical Order of Operations
Start where the guideline starts. For TRT injection frequency, weekly 75 to 100 mg, or the equivalent, is the reasonable default. Fortnightly 150 to 200 mg remains in the guideline and works for men who tolerate the swing; it is simply the schedule most likely to need changing.
Change frequency for a peak or trough problem. Hematocrit climbing, estradiol-type symptoms in the days after an injection, or a symptom cycle that tracks the calendar are all peak-or-trough problems, and splitting the dose addresses them directly. The order most clinicians use is weekly to twice weekly, then every other day if needed.
Change dose for an average problem. A midpoint level above target with no symptom cycling is a dose problem. More injections of the same total will not fix it; less testosterone will. Persistent low libido on an in-range level is neither, and needs a wider look.
Change one variable at a time, then wait. Steady state takes about five half-lives, so 3 to 4 weeks for cypionate or enanthate. Re-test at 6 to 8 weeks at the correct point in the new cycle. Changing dose, frequency and route in the same month makes the next lab uninterpretable.
Do not import cycle logic. Steroid-cycle habits, such as front-loading, stacking esters or treating a peak as the goal, have no place in replacement therapy, where the entire objective is a stable, physiological level. The difference is laid out in TRT vs steroid cycles.
TRT Injection Frequency: Common Questions
Is it better to inject testosterone once or twice a week?
Twice a week gives flatter blood levels, a lower estradiol peak and a smaller hematocrit rise for the same weekly dose. Once a week keeps levels within the normal range for most men and is the usual starting point. Twice weekly is the standard next step when hematocrit, estradiol symptoms or a weekly symptom cycle become a problem.
How often should testosterone cypionate be injected?
The Endocrine Society lists cypionate or enanthate at 75 to 100 mg weekly or 150 to 200 mg every two weeks. Most clinics now use weekly or twice-weekly dosing because the two-week schedule produces supraphysiological levels for several days followed by a trough near baseline.
Why do I feel bad before my next testosterone injection?
Because the level has fallen. On a two-week schedule, testosterone is back near the untreated baseline by day 13 to 14; even on weekly dosing the trough sits roughly 40 to 50 percent below the peak. Symptoms that track the injection calendar usually improve with a more frequent split of the same dose.
Does injecting more often lower estradiol?
It lowers the estradiol peak, because estradiol tracks the testosterone peak and the peak is smaller when the dose is split. The average estradiol over the week changes little. That is usually enough to resolve peak-related symptoms without an aromatase inhibitor.
Does TRT injection frequency affect hematocrit?
Yes. Injections raise hematocrit more than gels, and the stimulus is exposure above the normal range after each dose. Smaller, more frequent injections reduce that exposure and are the usual first change when hematocrit is climbing toward the 54 percent action threshold.
Can testosterone be injected subcutaneously instead of intramuscularly?
Yes. Weekly subcutaneous cypionate or enanthate produced normal-range levels in every patient in a 63-patient series, with only minor injection-site reactions, and weekly subcutaneous levels stayed within range across the whole week in a pharmacokinetic study. The smaller needle makes frequent dosing far more practical.
Is daily microdosing of testosterone better?
It is the highest TRT injection frequency and gives the flattest levels of any injectable schedule, similar to a gel. Whether that is better depends on whether fluctuation was the problem. For a man doing well on weekly injections it adds injections without adding benefit; for a man sensitive to peaks and troughs it can be the schedule that finally feels stable.
When should I test my levels after changing TRT injection frequency?
About 6 to 8 weeks after the change, once steady state has been reached, and at the correct point in the new cycle: midway between weekly injections, or just before an injection on twice-weekly or more frequent schedules. Include a CBC.
References
Related TRT Guides
Final Educational Note
This article summarizes published pharmacokinetic studies and clinical guidelines for educational purposes. Doses and schedules quoted are the ranges those sources describe, not recommendations; the right TRT injection frequency for any individual depends on his labs, symptoms, product and clinician.
MuscleScience does not prescribe or supply testosterone. For the wider series, start at the TRT and hormones hub and the bloodwork and health hub.
